Company profile

AdipoPharma company profile

AdipoPharma is a clinical stage biotech company developing PATAS a first-in-class whole-body insulin sensitizing therapeutic to treat Insulin resistance the primary cause of Type 2 Diabetes. Type 2 diabetes is the fastest chronic growing disease on the planet and is projected to globally effect over 1.3 billion people within the next 20 years. The worldwide silent growing insulin market (estimated to reach 100 billion by 2035) is a testament to the failure of the current anti-diabetic therapeutics currently available on the market. Cardiovascular disease, fatty liver disease, chronic kidney disease, blindness and neuropathy are its devastating complications resulting in enormous..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2022-07-01

Headquarters

Headquarters
Strasbourg, Grand Est, France
Postal code
67000
Country code
FR
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$10.6M
Last funding
Series A / $10.6M / 2024-11-11
Last equity funding
Series A / $10.6M
Investors
5
Lead investors
1
Founders
1
Articles
11

Founders and investors

Founders

Vincent MARION

Lead investors

Newton Biocapital

Investors

Good Growth CapitalInvestSudNewton BiocapitalOkeanosSambrinvest

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.